CD19 and congenital rubella syndrome: In a group of eight patients who also received anti-CD19 CAR-T cells with CD3ζ/4-1BB co-stimulatory signaling at our center before implementing prophylactic tocilizumab we observed all-grade CRS in 6/8 (75%) while grade 2 or higher occurred in five (62.5%), including one patient who experienced fatal CRS.